|
|
News Breaks | | | | February 22, 2013 | | 07:42 EDT |  | VVUS | EMA confirms refusal of marketing authorization for VIVUS weight loss drug
The Committee for Medicinal Products for Human Use previously adopted a negative opinion, recommending the refusal of the marketing authorization for the medicinal product Qsiva, intended for the treatment of obesity, from Vivus BV. The applicant requested a re-examination of the opinion. After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorization on February 21, the EMA announced. | |
|
News For VVUS From The Last 14 Days Check below for free stories on VVUS the last two weeks. |
|
|
| June 17, 2013 | | 07:11 EDT | | VVUS | VIVUS urges stockholders to vote on the GOLD proxy card
VIVUS mailed a letter to stockholders advising them to protect the value of their investment in VIVUS by voting the GOLD proxy card. The letter stated "VIVUS stockholders face an important decision at the upcoming 2013 VIVUS Annual Meeting of Stockholders. Your board and management team have made substantial progress in laying the foundation for Qsymia, and now we are poised to drive future sales by providing broad access to the millions of patients whose lives would benefit from this important therapy. While much progress has already been made, careful and timely execution of the next phase of our retail commercialization plan will be critical to the success of VIVUS. This phase of our retail commercialization plan, after REMS modification, requires a major pharmaceutical company to reach the primary care physicians. As such, we are in discussions with large pharmaceutical companies to explore opportunities as to how we may work together to maximize sales of Qsymia. We strongly believe that electing First Manhattan nominees at the Annual Meeting will jeopardize the progress we are making, and will throw VIVUS into turmoil. At this critical juncture in the company's history, FMC, which owns less than 10% of the company's stock, is trying to seize control of 100% of the VIVUS Board and your company. We strongly urge you not to jeopardize the important progress your Board and management team are making and risk your investment." | | | June 7, 2013 | | 07:04 EDT | | VVUS | VIVUS drug Qsymia cited in The Journal of Diabetes and Its Complications
 Subscribe for More Information | | | June 4, 2013 | | 11:17 EDT | | VVUS | First Manhattan mails proxy statement, sends letter to Vivus shareholders
Subscribe for More Information | |
|
|
|
|
|
|
